Business
VALEO PHARMA REPORTS RECORD SECOND QUARTER REVENUES
VALEO PHARMA REPORTS RECORD SECOND QUARTER REVENUES.
About this update from Valeo Pharma Inc.
[{"type":"text","content":"\n\n\n\nVALEO PHARMA REPORTS RECORD SECOND QUARTER REVENUES\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nVALEO PHARMA REPORTS RECORD SECOND QUARTER REVENUES\nCanada NewsWire\nMONTREAL, June 13, 2023\n\n\n\nSixth consecutive quarter of revenue growth at $13.6 million in Q2-23, up 184% over Q2-22.Sixth consecutive quarter of adjusted EBITDA loss reduction at $1.7 million, a 53% improvement over Q2-22, and down 24% compared to Q1-23Physicians prescribing Enerzair and Atectura reached 2,036 at the end of Q2-23, representing 29% growth from the prior quarter and a 355% increase year-over-year Total prescriptions for the 12 months ending April 30, 2023 exceeded 45,000, up 654% over April 30, 2022MONTREAL, June 13, 2023 /CNW/ - Valeo Pharma Inc. (TSX:VPH) (OTCQB: VPHIF) (FSE: VP2) (\"Valeo\" or the \"Company\"), a Canadian pharmaceutical company, today reported its financial results for the second quarter ended April 30, 2023.\n\n \n \n \n \n \n \n\n \nSecond quarter 2023 Results & Highlights:Record quarterly revenues of $13.6 million in Q2-23, compared to $4.8 million in Q2-22, up 184%, with Enerzair and Atecura up 271%.Record adjusted gross profit of $5.0 million in Q2-23 compared to $1.8 million in Q2-22, up 181%Q2-23 net loss of $6.5 million compared to $5.1 million in Q2-22,Q2-23 adjusted EBITDA loss of $1.7 million compared to a $3.6 million loss in Q2-22, a 53% reductionEnerzair and Atectura prescribing physicians reached 2,036 at the end of Q2-23, a 29% growth for the quarter and 355% increase year-over-yearTotal of 14,765 Enerzair and Atectura prescriptions during Q2-23, up 291% over Q2-22Total of 45,031 Enerzair and Atectura prescriptions over the last 12 months, up 654% year-over-year.\"Our second quarter financial and commercial performance was robust  and reflects our strong product portfolio and dynamic commercial team\", said Steve Saviuk, Valeo's Chief Executive Officer. \"Enerzair and Atectura's revenue and prescription growth is reflecting broadening adoption. As we are still in the early stages of their commercialization, we expect this trend...